Skip to Main Content

Rise and shine, everyone, another busy day is on the way. We can tell because the short people scurried off to their respective destinations faster than usual this morning. But busy is a good thing, or so they say. For those of you who may need some convincing, perhaps you would like to join us for a cup or three of stimulation. Our choice today is almond toffee, should you track this sort of thing. Meanwhile, here are a few tidbits to get you started. Once again, we wish you the best as you attempt to conquer the world. And as always, please do keep in touch. …

Lord Jim O’Neill, a former chief economist at Goldman Sachs who advised the U.K. government on antibiotic resistance, is shocked by drug makers failing to tackle drug-resistant infections and suggests the solution may be to “just take it away from them and take it over,” the BBC says. There has not been a new class of antibiotic since the 1980s. In a 2016 report, he proposed giving companies around $1 billion for each novel antibiotic developed. “There’s endless talk but there’s no progress in waking up the pharmaceutical industry to want to do this,” he says.


The Food and Drug Administration plans to revamp rules governing how medicines are manufactured, in an effort to ensure the safety of the U.S. drug supply as recalls of contaminated imports from developing countries widen, Bloomberg News writes. The proposed rule changes will focus on the raw materials used to produce drugs. The overhaul is in its early stages and may take several years to complete. More than a dozen companies have recalled drugs known as angiotensin II receptor blockers in the past eight months for containing three different potential carcinogens.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!